NCT05147961 (PRE-MED2) is a NA clinical trial of Digital Health in PreDiabetes, sponsored by University of Pisa.

Who is sponsoring NCT05147961?

NCT05147961 is sponsored by University of Pisa.

What drugs are being tested in NCT05147961?

Interventions in NCT05147961: Digital Health, Standard care.

What condition does NCT05147961 study?

NCT05147961 studies PreDiabetes.

Is NCT05147961 still recruiting?

NCT05147961 is currently status unknown. Last updated 5 December 2023.

Last reviewed 2023-12-05 · How we verify

NCT05147961: PRE-MED2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Precision Medicine for Preventing Type 2 Diabetes: a Step Forward

Status unknown NA Last updated 5 December 2023

What this trial tests

NA trial testing Digital Health in PreDiabetes in 300 participants. Status unknown.

Timeline

25 May 2022

Primary endpoint
1 October 2024

1 April 2025

Quick facts

Lead sponsor	University of Pisa
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	300
Start date	25 May 2022
Primary completion	1 October 2024
Estimated completion	1 April 2025
Sites	2 locations across Italy

Drugs / interventions tested

Digital Health
Standard care — full drug profile →

Conditions studied

PreDiabetes — all drugs for PreDiabetes →

Sponsor

University of Pisa

Who can join

Adults 18 to 70, any sex, with PreDiabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The prevalence of type 2 diabetes (T2D) has been rising rapidly with an increased burden to the healthcare system. As such T2D prevention is highly recommendable, and, theoretically, it can definitely be successful. However, though feasible T2D prevention is difficult to implement due to the heterogeneity of the disease that make response to population intervention (and treatment) only partially successful. Precision medicine aims to prevent chronic diseases by tailoring interventions or recommendations to a combination of a genetic background, metabolic profile, and lifestyle. Classification of individuals at risk into clusters that differ in their susceptibility to develop T2D may foster the identification of preventive interventions. Recent advances in omics technologies have offered opportunities as well as challenges in the use of precision medicine to prevent T2D. Moreover, new mobile health (mHealth) technologies have enhanced how diabetes is managed. However, little is still known about the effectiveness of mHealth technology as intervention tools for reducing diabetes risk.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current Insights into miRNA and lncRNA Dysregulation in Diabetes: Signal Transduction, Clinical Trials and Biomarker Discovery.
Pandey A, Ajgaonkar S, Jadhav N, Saha P, et al · · 2022 · cited 14× · PMID 36297381 · DOI 10.3390/ph15101269

Verify or expand the search:

Other recruiting trials for PreDiabetes

Currently open trials in the same condition.

NCT06897982 — Feasibility of a Nutrition Intervention for Patients With Prediabetes at a Federally Qualified Health Center · NA · recruiting
NCT06967558 — The Role of Islet GLP-1 in the Pathogenesis of Prediabetes · Phase 2 · recruiting
NCT06482944 — Whole Food for Families: A Pilot RCT of a Dietary Guidelines-Based Intervention to Prevent Type 2 Diabetes · NA · recruiting
NCT06989164 — Post Prandial Individual Responses to Different Foods · NA · recruiting
NCT07254572 — Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes · Phase 4 · recruiting

Other University of Pisa trials

Trials by the same sponsor.

NCT07520890 — Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs) · recruiting
NCT07444229 — Team-Based Learning Integrated Into Clinical Simulation in Nursing Students · NA · not yet recruiting
NCT07041983 — 24-h Energy Expenditure and Anti-obesity Medication · enrolling by invitation
NCT07510685 — Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial) · NA · completed
NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05147961 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pisa
Last refreshed: 5 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05147961.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing